New Twice-Daily inhaler shows promise for lung hypertension patients

NCT ID NCT04691154

First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 19 times

Summary

This study tests a new inhaled medicine called L606 for people with high blood pressure in the lungs (pulmonary arterial hypertension or related to lung disease). The goal is to see if switching to or starting L606, taken twice daily, is safe and tolerable. About 28 adults aged 18 to 80 will take part, with safety monitored over up to 48 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Arizona Pulmonary Specialists

    Scottsdale, Arizona, 85258, United States

  • Baylor Scott and White Research Institute

    Temple, Texas, 76508, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029-6504, United States

  • Mayo Clinic Jacksonville

    Jacksonville, Florida, 32224, United States

  • Summit Health Eastside Clinic

    Bend, Oregon, 97701, United States

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45267, United States

  • University of South Florida

    Tampa, Florida, 33606, United States

  • VA Greater Los Angeles Healthcare

    Los Angeles, California, 90073, United States

Conditions

Explore the condition pages connected to this study.